Compare Logitech International SA (LOGI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Neurocrine Biosciences Inc — how do they compare? Logitech International SA trades at $98.15 (market cap $14.46B), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Logitech International SA and Neurocrine Biosciences Inc are close in size by market cap, and Logitech International SA pays a 1.63% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LOGI | NBIX | |
|---|---|---|
Market Cap | $14.46B | $14.36B |
Volume | 349,547 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $126.69 | $185.50 |
52-Week Low | $85.84 | $123.10 |
Typical Hold Time | 92 Days | 23 Days |
Enterprise Value | $12.79B | $14.37B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $98.27, down 3.83% over the past day, amid a neutral technical backdrop. The stock shows strong fundamental health with consistent earnings beats, a robust net income margin of 16.28%, and a forward P/E of 18.64. Recent product launches, including the Zone Vibe Pro headset and MX Keypad, highlight innovation in the hybrid work and gaming segments. Cash flow trends are positive, with 2026 operating cash flow projected at $1.1 billion, supporting dividend payments and growth initiatives.
The investment outlook is balanced. Upside is supported by solid profitability, strategic partnerships like the SEGA alliance, and analyst consensus target of $107. However, risks include competitive pressures in peripherals, sensitivity to consumer spending, and the stock's high P/B ratio of 6.18. Investor sentiment is mixed, with technical indicators neutral and analyst ratings evenly split between buy, hold, and sell.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
